The EU Just Made Drug Exclusivity Conditional. Device Regulatory Teams Should Watch Why.

What if the length of your product's protected market period depended on evidence you still had to generate? For EU medicines, that is now the direction of travel.

The Council of the EU has adopted the "pharma package", a reform of EU pharmaceutical law. Protection after approval is no longer a single fixed period. Companies now earn extra years by meeting set criteria. This is pharma law, not device law, but we think device regulatory teams should watch it as a signal.

What actually changed?

On 28 September 2026 the Council adopted new rules for the EU pharmaceutical sector. RAPS Regulatory Focus reported that the vote was 26 to 1. The European Parliament still has to adopt the regulation and the directive before they are published in the Official Journal and enter into force.

The new structure works in layers:

Layer	What it gives	Condition
Regulatory data protection	8 years of exclusive rights to a new medicine's trial data	None
Market protection	1 year with no immediate generic or biosimilar competition	None
Extra market protection	Up to 2 more years, for a total of 11	Meeting set criteria, including addressing an unmet medical need
Transferable exclusivity voucher	1 extra year, usable on a product of the company's choice	Developing a priority antibiotic. Not usable on products above the sales threshold

Total protection is capped at 11 years, or 12 if a voucher is used. The voucher cannot be applied to a product with annual gross sales above €490 million (about $556 million) in the preceding four years. In other words, the biggest blockbusters are excluded by design.

Exclusivity now has a paper trail

Under a flat period, you cleared the gate once and the clock ran. Under this model, each extra year depends on something the company must be able to show.

The Council lists criteria such as comparative clinical trials, early application in the EU and trials in more than one member state. Unmet need is a separate route to a further year. The voucher adds a financial test on top: sales history decides whether you can use it at all.

That is our reading, not the Council's wording. But the logic is clear: protection is tied to evidence and outcomes, and the evidence has to exist, be documented and hold up when someone checks it.

Why does this matter even if you have never filed an MAA?

An MAA, or marketing authorisation application, is the filing a company submits to place a medicine on the EU market. Device manufacturers do not file one, so none of these rules apply to you. The reason to watch is the pattern, not the content.

Policy makers are showing a preference for incentives that follow criteria, not flat rewards. We cannot say device law will copy this, and nothing in the pharma package changes the MDR (Regulation (EU) 2017/745). Still, the direction fits what we see in the MDR reform debate: simplification of process, with the evidence bar kept in place.

For a device team, the practical lesson is about habit. If regulators increasingly ask "what can you show, and how current is it?", then documentation built once for a submission is a weak asset. A living evidence base is a strong one: literature searches on a schedule, post-market data linked to your clinical evaluation, and a clear record of why each conclusion holds.

Companies that treat regulatory documents as a one-time deliverable will keep rebuilding them under pressure. Those that keep them current will be able to use whatever incentives, faster pathways or flexibility the rules later offer. In our view, the ones who do not are the ones who will leave value on the table.

Key takeaways

• The Council adopted the pharma package on 28 September 2026. The Parliament still has to adopt it.
• Baseline protection is 8 years of data protection plus 1 year of market protection. It can reach 11 years if criteria are met.
• The transferable voucher adds a year but excludes products above €490 million in annual gross sales over four years.
• Protection now depends on evidence companies must prove, not on a one-time approval.
• This does not change the MDR. For device teams it is a leading indicator, and a reason to keep documentation current.

FAQ

Does the pharma package apply to medical devices?

No. It reforms EU rules for medicines. Devices remain under the MDR and the IVDR (Regulation (EU) 2017/746).

Is the pharma package law yet?

Not yet. The Council has adopted it, but Parliament must adopt the regulation and directive, which are then published in the Official Journal.

What is the transferable exclusivity voucher?

It gives one extra year of market protection, usable on a product the company chooses. It is meant to encourage development of priority antibiotics, and it cannot be used on products above the sales threshold.

Will device law move to conditional incentives too?

We do not know, and we would not assume it. We see the pharma package as a signal of policy direction, not a preview of specific device rules.

What should a device team do now?

Keep your clinical evaluation and post-market evidence current instead of rebuilding it before each audit. That is useful under today's MDR and under any version of the reform.

Want to turn your clinical documentation into a living evidence base? Contact the Qmedify Regulatory Team to talk through your plan.